Review Article
Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents
Table 1
Main pharmacodynamic/pharmacokinetic features of novel antiplatelet agents.
| | Family | Admin. route | Need for
metabolic
activation | Active
metabolite | Linkage
reversibility | Half
life (h) | Excretion |
| | Prasugrel | thienopyridines | Oral | Yes | Yes | No | 3.7 | Kidney | | Ticagrelor | Cyclopentyltria olo-pyrimidines | Oral | No | Yes | Yes | 6–12 | Kidney | | Cangrelor | Cyclopentyltria
olo-pyrimidines | Intravenous | No | No | Yes | 2.6–3.3 | Kidney |
|
|
